HIV DNA vaccine (PENNVAX-G) - Inovio
Alternative Names: HIV DNA vaccine against clades A, C and D - Inovio; PENNVAX G; PENNVAX-G DNA vaccine - Inovio/NIAID; PENNVAX-G-HIV-vaccineLatest Information Update: 28 Jul 2019
Price :
$50 *
At a glance
- Originator University of Pennsylvania
- Developer Inovio Pharmaceuticals
- Class AIDS vaccines; DNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 28 Jul 2019 No recent reports of development identified for phase-I development in HIV-infections(Prevention, In volunteers) in Kenya (IM, Injection)
- 28 Jul 2019 No recent reports of development identified for phase-I development in HIV-infections(Prevention, In volunteers) in Tanzania (IM, Injection)
- 28 Jul 2019 No recent reports of development identified for phase-I development in HIV-infections(Prevention, In volunteers) in Uganda (IM, Injection)